APOE

WRQ Sciences and Superfluid Dx., Inc. Announce Completion of Oversubscribed Series A Financing in Breakthrough Alzheimer's Disease Diagnostic Company Superfluid Dx

Retrieved on: 
Wednesday, December 20, 2023

PALO ALTO, Calif., Dec. 20, 2023 /PRNewswire/ -- WRQ Sciences and Superfluid Dx, Inc., announced today the completion of an oversubscribed Series A financing led by WRQ Sciences. With this transaction, WRQ Sciences has acquired majority ownership in the Alzheimer's Disease (AD) diagnostics company, Molecular Stethoscope, Inc., which is now renamed Superfluid Diagnostics, Inc. The Alzheimer's Drug Discovery Foundation's (ADDF) Diagnostics Accelerator (DxA) participated in the Series A financing.

Key Points: 
  • PALO ALTO, Calif., Dec. 20, 2023 /PRNewswire/ -- WRQ Sciences and Superfluid Dx, Inc., announced today the completion of an oversubscribed Series A financing led by WRQ Sciences.
  • With this transaction, WRQ Sciences has acquired majority ownership in the Alzheimer's Disease (AD) diagnostics company, Molecular Stethoscope, Inc., which is now renamed Superfluid Diagnostics, Inc.
  • "One million Americans per year develop Alzheimer's Disease and the need for a fast and accurate diagnostic test is acute and expanding," said Gajus Worthington, Superfluid Diagnostics' CEO and Managing Director of WRQ Sciences.
  • The breakthrough work at Superfluid Diagnostics will transform the Alzheimer's Disease diagnostic landscape."

New Research Shows High Accuracy of Precivity™ Blood Biomarkers in the Evaluation of Brain Amyloid in Pre-Clinical Alzheimer's Disease

Retrieved on: 
Tuesday, November 7, 2023

C2N analyzed the biomarkers using its high-resolution mass spectrometry (MS) analytical platform as part of this study.

Key Points: 
  • C2N analyzed the biomarkers using its high-resolution mass spectrometry (MS) analytical platform as part of this study.
  • All participants underwent amyloid PET scans, and 340 (32%) participants had positive PET scan findings (defined as Centiloid scale > 20).
  • Among the individual biomarkers evaluated, plasma p-tau217/np-tau217 had highest accuracy followed next by Aβ42/Aβ40 and last by p-tau181/np-tau181 for identifying amyloid PET status.
  • “The blood biomarkers with the highest performance in the study are the biomarkers highlighted in the Precivity blood tests, demonstrating the application of these biomarkers for important research purposes.

uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

Retrieved on: 
Tuesday, October 24, 2023

LEXINGTON, Mass.

Key Points: 
  • LEXINGTON, Mass.
  • and AMSTERDAM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that 12 data presentations, including two oral presentations, will be delivered at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting being held October 24-27 in Brussels, Belgium.
  • “Our multiple presentations at ESGCT demonstrate uniQure’s continued leadership in advancing important research within the field of gene therapy, as well as highlight our industry-leading expertise in AAV gene therapy manufacturing,” stated Richard Porter, Ph.D., Chief Business and Scientific Officer at uniQure .
  • “We look forward to sharing these presentations that feature our technology and platform experience across numerous programs.”
    Specific details on uniQure’s presentations taking place at ESGCT include:
    Presenter: Richard Porter, Chief Business and Scientific Officer, uniQure
    Session Title and Location: CNS & sensory diseases II, Session 10a, Shed 2A
    Session Title and Location: CNS & sensory diseases I, Session 2c, Maison de la Poste
    Title: Pivotal safety studies for AMT-260, a novel AAV9-dual microRNA-based vector targeting GRIK2 for the treatment of temporal lobe epilepsy (Poster #433)
    Presenter: Nick Pearson, Sr. Director Toxicology & Translational Safety, Non-Clinical, uniQure
    Poster Session Date and Time: Wednesday, October 25, 17:00 – 18:15, Thursday, October 26, 20:30 – 21:30 GMT+2
    Poster Session Date and Time: Wednesday, October 25, 18:15 – 19:30, Thursday October 26, 19:30 – 20:30 GMT+2
    Poster Session Date and Time: Wednesday, October 25, 17:00 – 18:15, Thursday, October 26, 20:30 – 21:30 GMT+2
    Title: Silence and replace as potential treatment for Alzheimer Disease: in concert lowering toxic APOE and augmenting protective APOE (Poster #049)
    Poster Session Date and Time: Wednesday, October 25, 17:00 – 18:15, Thursday, October 26, 20:30 – 21:30 GMT+2
    Poster Session Date and Time: Wednesday, October 25, 18:15-19:30, Thursday, October 26, 19:30-20:30 GMT+2
    Poster Session Date and Time: Wednesday, October 25, 18:15-19:30, Thursday, October 26, 19:30-20:30 GMT+2
    Presenter: Erich Ehlert, Director – Process Development – Chemistry, Manufacturing and Controls, uniQure
    Poster Session Date and Time: Wednesday, October 25, 17:00-18:15, Thursday, October 26, 20:30-21:30 GMT+2
    Poster Session Date and Time: Wednesday, October 25, 17:00-18:15, Thursday, October 26, 20:30-21:30 GMT+2
    Poster Session Date and Time: Wednesday, October 25, 18:15-19:30, Thursday, October 26, 19:30-20:30 GMT+2
    Presenter: Zandra Félix Garza, Project Manager- BPU – Cells, Seeds and Research Supply, uniQure
    Poster Session Date and Time: Wednesday, October 25, 17:00-18:15, Thursday, October 26, 20:30-21:30 GMT+2

NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s Disease

Retrieved on: 
Tuesday, September 26, 2023

Deletion of APOE has been demonstrated to limit disease in multiple AD models.

Key Points: 
  • Deletion of APOE has been demonstrated to limit disease in multiple AD models.
  • In preclinical AD animal models, NC181 has demonstrated differentiation from amyloid targeted therapies.
  • Key findings from the study include:
    NC181 binds to amyloid associated ApoE4, resulting in amyloid clearance and prevention of amyloid deposition in mice.
  • Additional studies to characterize NC181 as a potential therapeutic for AD and CAA are ongoing.

BioVie Presents Data Highlighting Baseline Characteristics of Study Population in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer’s Disease

Retrieved on: 
Monday, September 11, 2023

CARSON CITY, Nev., Sept. 11, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that preliminary baseline data from its multicenter, randomized, placebo-controlled Phase 3 study (NCT04669028) of NE3107 in patients with mild to moderate Alzheimer’s Disease (AD) was presented as a poster at the American Neurological Association (ANA) annual meeting, being held September 11-13, 2023 in Philadelphia, PA.

Key Points: 
  • The poster, Metabolic Dysregulation in Probable Alzheimer’s Disease (Christopher Reading, et al), is being presented by Joseph Palumbo, Chief Medical Officer of BioVie, and highlights the preliminary baseline metabolic and inflammation characteristics from the Phase 3 study population (see Table 1).
  • “Instead, it provides an understanding of the patient population at the start of the trial, as understood to date.
  • At baseline, the majority of the study population are coded with abdominal obesity (85%), hypertension (61%), and impaired glucose metabolism (IFG/T2D; 52%).
  • Both Aβ+ and Aβ− patients with dementia were enrolled in the study and had, at baseline, comparable CDR-SB scores indicative of mild dementia.

Melanoma Research Alliance Announces 2023 Dermatology Fellowship Award Recipients

Retrieved on: 
Thursday, July 20, 2023

WASHINGTON, July 20, 2023 /PRNewswire/ -- The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research, is proud to announce its 2023 Dermatology Fellowship Award recipients.

Key Points: 
  • WASHINGTON, July 20, 2023 /PRNewswire/ -- The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research, is proud to announce its 2023 Dermatology Fellowship Award recipients.
  • MRA's Dermatology Fellowship program is building a pipeline of scientists and clinicians who specialize in melanoma, the deadliest form of skin cancer and the fifth most common cancer in the United States.
  • The awardees, all early-career dermatologists or researchers focused on dermatology, will each receive a $50,000 grant to support an independent research project focused on advancing melanoma prevention or detection.
  • 2023 MRA Dermatology Fellowship Awardees:

BioVie Presents Data Highlighting Role of Insulin Resistance and Neuroinflammation in the Development of Mild to Moderate in Alzheimer’s Disease

Retrieved on: 
Monday, June 26, 2023

NE3107 is an oral small molecule, blood-brain permeable anti-inflammatory insulin sensitizer that binds extracellular signal-regulated kinase.

Key Points: 
  • NE3107 is an oral small molecule, blood-brain permeable anti-inflammatory insulin sensitizer that binds extracellular signal-regulated kinase.
  • BioVie’s Phase 3 trial is the largest study to date to evaluate the safety and efficacy of NE3107 in patients with AD.
  • NE3107 is the only anti-inflammatory agent currently in phase 3 development for AD.
  • Additional subgroup analysis revealed higher degrees of impaired glucose metabolism and insulin resistance among the APOE ε4− patients compared to their APOE ε4+ counterparts and comparable baseline MMSE scores, indicating that both groups had mild to moderate cognitive impairment.

Fujirebio further extends its fully automated blood-based biomarker portfolio with the fully automated Lumipulse® G ApoE4 and Lumipulse® G Pan-ApoE assays for Research Use Only

Retrieved on: 
Friday, March 31, 2023

Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G ApoE4 and Lumipulse G Pan-ApoE assays for the fully automated LUMIPULSE® G Systems.

Key Points: 
  • Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G ApoE4 and Lumipulse G Pan-ApoE assays for the fully automated LUMIPULSE® G Systems.
  • The two new automated blood-based biomarker assays are available for Research Use Only.
  • The APOE gene has three different alleles (ε2, ε3, ε4) that encode for three different ApoE isoforms (ApoE2, ApoE3, and ApoE4), resulting in 6 different phenotypes1.
  • In this regard, ApoE as a protein biomarker can be used in research to determine its value alone or as part of a panel of plasma biomarkers2.

uniQure to Participate in Multiple Upcoming Industry Conferences in March

Retrieved on: 
Thursday, March 2, 2023

Mr. Kapusta also will participate in a panel discussion, “Genetic Medicines Corporate Panel,” on March 6 from 10:30 – 11:30 a.m.

Key Points: 
  • Mr. Kapusta also will participate in a panel discussion, “Genetic Medicines Corporate Panel,” on March 6 from 10:30 – 11:30 a.m.
  • The live webcast of this event can be accessed through the link displayed in the Investors & Media section of the uniQure website.
  • Members of uniQure’s management team will participate in virtual investor meetings on Tuesday, March 28.
  • The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Media section of the uniQure website.

Inspirna Announces Interim Data from Phase 1b/2 Study of Abequolixron (RGX-104) in Relapsed or Refractory Lung Cancer

Retrieved on: 
Thursday, January 5, 2023

Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule cancer therapeutics, announced today interim data from its ongoing Phase 1b/2 clinical trial of abequolixron in patients with non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC).

Key Points: 
  • Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule cancer therapeutics, announced today interim data from its ongoing Phase 1b/2 clinical trial of abequolixron in patients with non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC).
  • Abequolixron is currently being evaluated in a Phase 1b/2 clinical trial in combination with docetaxel in second- or third-line (2/3L) NSCLC as well as second-line (2L) SCLC.
  • The primary objectives of the study include characterizing the safety profile and the antitumor activity of the abequolixron and docetaxel combination.
  • In addition, this Phase 1b/2 study includes an ongoing expansion arm of abequolixron in combination with Yervoy (ipilimumab) in second- or third-line endometrial cancer as part of a clinical collaboration with Bristol Myers Squibb.